Clinical Trial

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2023 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the venous/lymphatic vascular organisations. The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2015-12-18; most recent amendment 2023-02-23.
Trial Details
NCT Number NCT02638389
Lead Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions Vascular Malformations
Enrollment 250 participants
Start Date 2016-01-25
Primary Completion 2025-04-01 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2023-02-24